Medical device company DexCom (NASDAQ:DXCM) reported Q3 2026 results , with revenue up 11.2% year on year to $1.34 billion. The company expects the full year’s revenue to be around $5.23 billion, close to analysts’ consensus estimates.

Dexcom raised full-year revenue guidance again, to $5.20 billion to $5.25 billion, after topping expectations on both lines. Management also lifted non-GAAP operating margin guidance to about 24%

DexCom logged higher third-quarter sales and authorized a share-buyback program of up to $1 billion. The maker of glucose monitors posted a profit of $275.1 million, or 72 cents a share, compared with $283.8 million, or 70 cents a share, a year earlier.

(Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2026. Third Quarter 2026

DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company’s one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.

The new 2026 data highlights an urgent opportunity for people with Type 2 diabetes: closing the gap between CGM's proven, transformative impact and the millions with Type 2 who lack awareness or access to this solution. Key takeaways from the 2026 report released today include:

The company's earnings came in at $275.1 million, or $0.72 per share. This compares with $283.8 million, or $0.70 per share, last year. Excluding items, DexCom Inc. reported adjusted earnings of $275.0 million or $0.73 per share for the period. The company's revenue for the period rose 11.2% to $1.344 billion from $1.209 billion last year.

DexCom develops and markets continuous glucose monitoring (CGM) systems, a type of device that continuously tracks blood sugar levels. The technology isn't exactly new anymore, and it has enjoyed increased adoption over the past decade, partly thanks to ...

EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE Mark (Conformité Européenne) for the Dexcom G7 ...

DexCom (DXCM) said its Board of Directors authorized and approved a share repurchase program of up to $1 billion of Dexcom’s outstanding common stock, par value $0.001 per share, with a repurchase period ending no later than December 31,